Xponance Inc. Sells 256 Shares of Masimo Co. (NASDAQ:MASI)

Xponance Inc. lessened its holdings in Masimo Co. (NASDAQ:MASI) by 2.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,635 shares of the medical equipment provider’s stock after selling 256 shares during the period. Xponance Inc.’s holdings in Masimo were worth $1,129,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MASI. Massmutual Trust Co. FSB ADV grew its position in Masimo by 140.6% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 142 shares during the last quarter. Byrne Asset Management LLC acquired a new stake in shares of Masimo during the fourth quarter valued at about $28,000. NBC Securities Inc. acquired a new stake in shares of Masimo during the third quarter valued at about $34,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Masimo during the fourth quarter valued at about $36,000. Finally, Fifth Third Bancorp boosted its stake in shares of Masimo by 145.8% during the fourth quarter. Fifth Third Bancorp now owns 590 shares of the medical equipment provider’s stock valued at $69,000 after purchasing an additional 350 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

Analysts Set New Price Targets

MASI has been the topic of a number of recent research reports. Stifel Nicolaus raised Masimo from a “hold” rating to a “buy” rating and lifted their price target for the company from $148.00 to $170.00 in a research note on Monday, April 15th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $121.00 price objective (up from $107.00) on shares of Masimo in a research note on Tuesday, January 30th. StockNews.com raised Masimo from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Needham & Company LLC lowered Masimo from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, Piper Sandler lifted their price objective on Masimo from $70.00 to $117.00 and gave the stock a “neutral” rating in a research note on Monday, February 26th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $137.43.

Masimo Price Performance

Shares of MASI opened at $135.92 on Thursday. Masimo Co. has a 52-week low of $75.22 and a 52-week high of $195.82. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18. The business’s 50 day moving average price is $135.72 and its two-hundred day moving average price is $115.82. The firm has a market cap of $7.19 billion, a PE ratio of 90.01 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The firm had revenue of $548.90 million for the quarter, compared to analyst estimates of $545.69 million. During the same period in the previous year, the firm earned $1.32 earnings per share. The company’s revenue was down 11.0% compared to the same quarter last year. On average, equities analysts anticipate that Masimo Co. will post 3.51 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.